Загрузка...

Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia

Tyrosine kinase inhibitor treatment of chronic myeloid leukemia (CML) has demonstrated beneficial effects. However, resistance to tyrosine kinase inhibitors and disease relapse are still a challenge for CML therapy. In this study, we analyzed bone marrow samples from 149 CML patients and 15 control...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Death Dis
Главные авторы: Li, Wei, Ji, Min, Lu, Fei, Pang, Yihua, Dong, Xin, Zhang, Jingru, Li, Peng, Ye, Jingjing, Zang, Shaolei, Ma, Daoxin, Ji, Chunyan
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6113287/
https://ncbi.nlm.nih.gov/pubmed/30154435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0900-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!